Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and drf 2725

rosiglitazone has been researched along with drf 2725 in 16 studies

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (68.75)29.6817
2010's5 (31.25)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bajji, AC; Chakrabarti, R; Juluri, S; Kalchar, S; Lohray, BB; Lohray, VB; Mamidi, NV; Misra, P; Padakanti, S; Poondra, RR; Rajagopalan, R; Vikramadithyan, RK1
Andersen, AS; Brand, CL; Bury, PS; Fleckner, J; Jeppesen, L; Lehmann, SV; Mogensen, JP; Mortensen, SB; Panajotova, V; Pettersson, I; Polivka, Z; Rasmussen, HB; Sauerberg, P; Sindelar, K; Sturis, J; Svensson, LA; Wassermann, K; Wöldike, HF; Wulff, EM; Ynddal, L1
Albrektsen, T; Bury, PS; Din, N; Fleckner, J; Frederiksen, KS; Jeppesen, L; Mogensen, JP; Mortensen, SB; Nehlin, J; Pettersson, I; Sauerberg, P; Svensson, LA; Wassermann, K; Wulff, EM; Ynddal, L1
Deussen, HJ; Ebdrup, S; Fleckner, J; Frost Jensen, A; Mortensen, SB; Nygaard, L; Pettersson, I; Pridal, L; Rasmussen, HB; Sauerberg, P1
Henke, BR1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Kagechika, K; Kubo, H; Shibata, Y; Usui, H; Yamaguchi, M1
Hashimoto, Y; Ishikawa, M; Makishima, M; Noguchi-Yachide, T; Okazaki, S; Shioi, R; Yamaguchi, T1
Andersen, B; Brand, CL; Fleckner, J; Fledelius, C; Gotfredsen, CF; Hansen, BF; Sauerberg, P; Sturis, J; Wassermann, K; Ye, JM1
Cooney, GJ; Ellis, B; Iglesias, MA; Jensen, PB; Kraegen, EW; Larsen, PJ; Sørensen, RV; Wassermann, K; Watson, DG; Wood, L; Ye, JM1
Cai, ZF; Guo, ZR1
Roden, M; Stingl, H1
Kaya, T; Sheu, SH; Vajda, S; Waxman, DJ1
Chopra, B; Georgopoulos, NT; Hinley, J; Nicholl, A; Oleksiewicz, MB; Southgate, J1

Reviews

3 review(s) available for rosiglitazone and drf 2725

ArticleYear
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
    Journal of medicinal chemistry, 2004, Aug-12, Volume: 47, Issue:17

    Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors

2004
[Peroxisome poliferator-activated receptors and their modulators].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2004, Volume: 39, Issue:2

    Topics: Animals; Humans; Oxazines; Phenylpropionates; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors

2004
[Future targets in the treatment of type 2 diabetes].
    Wiener klinische Wochenschrift, 2004, Apr-30, Volume: 116, Issue:7-8

    Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Forecasting; Glucagon; Glucagon-Like Peptide 1; Glucose; Glycated Hemoglobin; Glycogen Synthase Kinase 3; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Peroxidation; Metabolic Syndrome; Mice; Oxazines; Peptide Fragments; Phenylpropionates; Protein Precursors; Rats; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factors

2004

Other Studies

13 other study(ies) available for rosiglitazone and drf 2725

ArticleYear
(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.
    Journal of medicinal chemistry, 2001, Aug-02, Volume: 44, Issue:16

    Topics: Animals; Biological Availability; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Mice; Oxazines; Phenylpropionates; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors; Triglycerides

2001
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
    Journal of medicinal chemistry, 2002, Feb-14, Volume: 45, Issue:4

    Topics: Animals; Blood Glucose; Carbazoles; Cholesterol; Cholesterol, Dietary; Crystallography, X-Ray; Drug Evaluation, Preclinical; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Molecular; Nuclear Proteins; Phenylpropionates; Pioglitazone; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides

2002
Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.
    Bioorganic & medicinal chemistry letters, 2003, Jan-20, Volume: 13, Issue:2

    Topics: Animals; Blood Glucose; Glucose Tolerance Test; Insulin; Male; Mice; Models, Molecular; Molecular Conformation; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors

2003
Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
    Journal of medicinal chemistry, 2003, Apr-10, Volume: 46, Issue:8

    Topics: Binding Sites; Crystallography, X-Ray; Hypoglycemic Agents; Ligands; Models, Molecular; Oxazines; Phenylpropionates; Radioligand Assay; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors

2003
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
    Bioorganic & medicinal chemistry letters, 2012, Dec-01, Volume: 22, Issue:23

    Topics: Animals; Blood Glucose; Drug Design; Mice; PPAR alpha; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones; Triglycerides; Weight Gain

2012
Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Bioorganic & medicinal chemistry letters, 2017, 07-15, Volume: 27, Issue:14

    Topics: Acetamides; Binding Sites; Genes, Reporter; HEK293 Cells; Humans; Ligands; PPAR alpha; PPAR delta; Protein Binding; Stereoisomerism; Thiazolidinediones

2017
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
    American journal of physiology. Endocrinology and metabolism, 2003, Volume: 284, Issue:4

    Topics: Animals; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycated Hemoglobin; Glycogen; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Liver; Male; Oxazines; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors

2003
PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.
    American journal of physiology. Endocrinology and metabolism, 2003, Volume: 284, Issue:3

    Topics: Animals; Dietary Fats; Fatty Liver; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Muscle, Skeletal; Oxazines; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors

2003
Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
    Biochemistry, 2005, Feb-01, Volume: 44, Issue:4

    Topics: Alkanesulfonates; Binding Sites; Cinnamates; Computational Biology; Humans; Ligands; Oxazines; Oxazoles; Phenylpropionates; PPAR gamma; Protein Binding; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Rosiglitazone; Solvents; Thiazoles; Thiazolidinediones; Thiazolidines; Tyrosine

2005
Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.
    Cell proliferation, 2009, Volume: 42, Issue:5

    Topics: Apoptosis; Calcium; Calcium Channels; Caspase 3; Caspase 9; Cell Division; Cells, Cultured; Chromans; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Membrane Potential, Mitochondrial; Oxazines; p38 Mitogen-Activated Protein Kinases; Peroxisome Proliferator-Activated Receptors; Phenoxyacetates; Phenylpropionates; Rosiglitazone; Thiazolidinediones; Troglitazone; Urothelium

2009